- Home
- NVO vs LLY Comparison
NVO vs LLY Comparison
Compare NVO & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | LLY |
|---|---|---|
| Founded | 1923 | 1876 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.2B | 979.6B |
| IPO Year | 2001 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NVO | LLY |
|---|---|---|
| Price | $48.04 | $1,256.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $51.00 | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 12.4M | 2.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.19% | 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | N/A | ★ 16.19 |
| Revenue | N/A | ★ $65,179,000,000.00 |
| Revenue This Year | N/A | $27.15 |
| Revenue Next Year | $3.70 | $16.04 |
| P/E Ratio | ★ $13.60 | $77.08 |
| Revenue Growth | N/A | ★ 44.70 |
| 52 Week Low | $35.12 | $712.05 |
| 52 Week High | $64.16 | $1,292.65 |
Technical Indicators
Market Signals| Indicator | NVO | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 59.42 |
| Support Level | $47.93 | $1,148.95 |
| Resistance Level | $50.45 | N/A |
| Average True Range (ATR) | 0.95 | 36.82 |
| MACD | 0.13 | 5.22 |
| Stochastic Oscillator | 94.29 | 72.88 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.